These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 23020725)

  • 41. On the pharmacogenetics of non-small cell lung cancer treatment.
    Santarpia M; Rolfo C; Peters GJ; Leon LG; Giovannetti E
    Expert Opin Drug Metab Toxicol; 2016; 12(3):307-17. PubMed ID: 26761638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New generations of targeted therapies fighting the resistance in solid tumors.
    Barthélémy P; Aftimos P; Awada A
    Curr Opin Oncol; 2015 May; 27(3):243-9. PubMed ID: 25715325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The emerging role of microRNAs in resistance to lung cancer treatments.
    MacDonagh L; Gray SG; Finn SP; Cuffe S; O'Byrne KJ; Barr MP
    Cancer Treat Rev; 2015 Feb; 41(2):160-9. PubMed ID: 25592062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel targeted agents for the treatment of lung cancer in China.
    Liu SY; Mok T; Wu YL
    Cancer; 2015 Sep; 121 Suppl 17():3089-96. PubMed ID: 26331815
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeted agents in the management of small cell lung cancer - present and future.
    Srivastava R; Lebowicz Y; Jamil MO
    Drugs Today (Barc); 2018 Aug; 54(8):479-488. PubMed ID: 30209442
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time.
    Shepherd FA
    J Clin Oncol; 2008 May; 26(15):2426-7. PubMed ID: 18458043
    [No Abstract]   [Full Text] [Related]  

  • 47. ROS1-targeted therapy in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2012 Dec; 10(12):827-8. PubMed ID: 23271356
    [No Abstract]   [Full Text] [Related]  

  • 48. Current Landscape of Targeted Therapy in Lung Cancer.
    Mayekar MK; Bivona TG
    Clin Pharmacol Ther; 2017 Nov; 102(5):757-764. PubMed ID: 28786099
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Molecular target therapy: a new method in treatment of lung cancer].
    Chen LA
    Zhonghua Yi Xue Za Zhi; 2006 Oct; 86(37):2599-602. PubMed ID: 17198582
    [No Abstract]   [Full Text] [Related]  

  • 50. Resistance to Therapy.
    Rivera G; Wakelee HA
    Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy.
    Savonarola A; Palmirotta R; Guadagni F; Silvestris F
    Pharmacogenomics J; 2012 Aug; 12(4):277-86. PubMed ID: 22760589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Targeted therapies in oncology come of age.
    Klein A
    Clin Ther; 2013 Sep; 35(9):1256-7. PubMed ID: 24054702
    [No Abstract]   [Full Text] [Related]  

  • 54. Epidermal growth factor receptor: an important target in esophageal cancer.
    Hong L; Han Y; Brain L
    Expert Opin Ther Targets; 2013 Oct; 17(10):1179-85. PubMed ID: 23855932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lung cancer in 2014: optimizing lung cancer treatment approaches.
    Rosell R; Karachaliou N
    Nat Rev Clin Oncol; 2015 Feb; 12(2):75-6. PubMed ID: 25533943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New strategies to develop new medications for lung cancer and metastasis.
    Zhao Y; Adjei AA
    Cancer Metastasis Rev; 2015 Jun; 34(2):265-75. PubMed ID: 25944554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer.
    Maftouh M; Avan A; Galvani E; Peters GJ; Giovannetti E
    Crit Rev Oncog; 2013; 18(4):317-26. PubMed ID: 23614618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.
    Rihawi K; Giampieri R; Scartozzi M; Pusceddu V; Bonotto M; Fasola G; Cascinu S; Aprile G
    Expert Opin Investig Drugs; 2015; 24(9):1185-98. PubMed ID: 26044119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
    Meador CB; Hata AN
    Pharmacol Ther; 2020 Jun; 210():107522. PubMed ID: 32151666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expanding targeted therapies for NSCLC.
    Cancer Discov; 2014 Dec; 4(12):OF1. PubMed ID: 25477108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.